Currently trading under six cents. Working with Becton Dickinson to develop test to detect early stage Alzheimers. Potential $500,000,000 annual market.
Company's patented MANF drug has several orphan indications.
Zachs' analyst Jason Napadano put a .20 price target on the stock and a buy rating on Monday.
AMBS was trading at 1/10th of a penny early in 2012 before the hype machines got going. They will need to raise plenty of money and it will be at 2c if they are lucky...Capiche
Not willing to get raped by another bio just yet .... but thks for the tip